These results confirm the previous preclinical findings that loss of PTEN or activation of PIK3CA through hotspot mutations (E545K in the HD in exon 9 and H1047R in KD exon 20) confer resistance to lapatinib in HER2 overexpressing BC cells [139]. The gene discussed is ERBB2; the disease is breast cancer.